SeekingAlpha · Mar 14, 2026
U.S. IPO Weekly Recap: PayPay Prices US IPO Below The Range But Climbs 32%
Two IPOs, one direct listing, and three SPACs came to the market this past week, and one major issuer joined the pipeline. Read more here.
GR
NASDAQ · GRAY
Graybug Vision, Inc.
Healthcare · Biotechnology
$5.50
Down-$0.67 (-10.80%)
Updated Aug 23, 2026, 7:33 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 120.98M
- P/E ratio
- -7,478.67
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 24.63K
- Avg. volume
- 7.47K
Price performance
GRAY price history
1M range · 0 trading sessions · Daily adjusted prices
GRAY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest GRAY news
The latest Smart Investors Daily articles mentioning GRAY.
Stock researchCompany · Overview
GRAY research
Overview
Company profile and research snapshot.
Company profile
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2022 | Piper Sandler | Neutral | — |
| Mar 17, 2022 | Cantor Fitzgerald | Overweight | — |
| May 13, 2021 | Needham | Hold | — |
| May 13, 2021 | SVB Leerink | Market Perform | — |
| Mar 10, 2021 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 20, 2026
U.S. IPO Weekly Recap: IPO Market Stays Fairly Quiet During The Short Holiday Week
seekingalpha.com · Dec 10, 2025
ETHE Vs. ETH: Which Grayscale Ethereum ETF Is Better?
Grayscale Ethereum Trust ETF remains a total avoid due to its persistently high 2.5% expense ratio, despite now staking most of the assets under management. Grayscale Ethereum Mini Trust ETF offers a vastly superior net yield at 0.15% fees and a competitive staking ratio, making it the preferred long-term exposure. ETHE's high fees fully offset staking rewards, resulting in a negative net yield even before factoring in Ethereum's inflation rate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
